KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
Adding pembrolizumab to trastuzumab and chemotherapy improved response and progression-free survival in HER2-positive advanced gastric cancer, with the benefit concentrated in tumours that also express PD-L1.
Overview
Phase 3 placebo-controlled trial of 698 patients with untreated HER2-positive advanced gastric or junctional adenocarcinoma randomised to pembrolizumab or placebo with trastuzumab and fluoropyrimidine-platinum chemotherapy.
Median progression-free survival was 10.0 versus 8.1 months (hazard ratio 0.72) overall and 10.8 versus 7.2 months in PD-L1 combined positive score 1 or more (hazard ratio 0.70); response was 73 versus 60 percent, and the final analysis showed an overall survival benefit in the PD-L1-positive population (20.0 versus 15.7 months).
- Median progression-free survival 10.0 vs 8.1 months; hazard ratio 0.72.
- Combined positive score 1 or more: overall survival 20.0 vs 15.7 months at final analysis.
Pembrolizumab with trastuzumab and chemotherapy is the first-line standard for HER2-positive gastric cancer with a PD-L1 combined positive score of 1 or more.
- No benefit in PD-L1-negative tumours (about 15 percent), leading to a label restriction.
Similar pages
not linked directly; found by shared links- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
- Key paperKEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma
Shares The Lancet, Pembrolizumab.
- Key paperKEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma
Shares The Lancet, Pembrolizumab.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Trastuzumab, Pembrolizumab.
- PairingHER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
- Key paperDESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shares HER2-positive gastric cancer, Trastuzumab.
- Key paperLEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma
Shares The Lancet, Pembrolizumab.